Cargando…
Thiazolidinediones (TZDs) enhance insulin secretory response via GPR40 and adenylate cyclase (AC)
Thiazolidinediones are synthetic PPARγ ligands that enhance insulin sensitivity, and that could increase insulin secretion from β‐cells. However, the functional role and mechanism(s) of action in pancreatic β‐cells have not been investigated in detail.
Autores principales: | Hwang, Mina, Kim, Hyo‐Sup, Jin, Sang‐Man, Hur, Kyu Yeon, Kim, Jae‐Hyeon, Lee, Moon‐Kyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290135/ https://www.ncbi.nlm.nih.gov/pubmed/34133753 http://dx.doi.org/10.1002/jcp.30467 |
Ejemplares similares
-
What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin?
por: Curtiss, Frederic R.
Publicado: (2006) -
PPARγ activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFβ signalling
por: Jarrar, Mohammed H, et al.
Publicado: (2007) -
Establishment and characterization of a new class of adenylate cyclases (class VII ACs) in plants
por: Liu, Zhiguo, et al.
Publicado: (2023) -
TZDs and Bone: A Review of the Recent Clinical Evidence
por: Schwartz, Ann V.
Publicado: (2008) -
Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
por: Schwartz, Ann V.
Publicado: (2006)